The Effects of VEGF-B Signaling Pathway in Obesity and Metabolic Disease

Obesity Clinical Trial

— Obesity  

Official title:

The Effects of VEGF-B Signaling Pathway in Obesity and Metabolic Disease

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03164005
• Other study ID #: 2016CFA025
• Status: Completed
• Start date: April 20, 2017
• Est. completion date: March 1, 2018

Study information

• Verified date: April 2021
• Source: Wuhan Union Hospital, China
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The investigators will enroll about 120 subjects from the hospital's healthcare center. The investigators will collect the basic informations, blood pressure, body mass index, fasting blood glucose and fasting blood lipids of each subject. The investigators will collect the blood samples and then test them for fasting insulin levels, VEGF-B levels, the gene promoter region methylation status and the genomic protein methylation levels of the VEGF-B gene of the cells，and finally do the statistical analysis.

Description:

The investigators will enroll about 120 subjects from the hospital's healthcare center, and these 120 subjects will be divided into four groups: normal weight with or without metabolic diseases and obesity with or without metabolic diseases. Each group has 30 subjects. The investigators will collect the basic information(name, gender，age, medical history，family history, etc.), blood pressure, body mass index, fasting blood glucose and fasting blood lipids of each subject from the healthcare center. The investigators will collect the blood samples of each subject,separate the plasma and then test the fasting insulin, VEGF-B levels by ELISA. The investigators will separate the peripheral blood mononuclear cells from the blood, and then test the gene promoter region methylation status of the VEGF -B gene by PCR and the bisulfite-modified sequencing and test the genomic protein methylation level of the VEGF-B gene by chromatin immunoprecipitation assay(CHIP) and real-time quantitative PCR of the cells，and finally do the statistical analysis.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 194
• Est. completion date: March 1, 2018
• Est. primary completion date: September 1, 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• NA

Exclusion Criteria:

• subjects with active history insulin treatment; and female participant pregnant at the time of recruitment.

Related Conditions & MeSH terms

• Metabolic Disease
• Metabolic Diseases
• Obesity

Locations

Country	Name	City	State
China	Department of Endocrinology, Union Hospital,Tongji Medical College, Huazhong University of Science and Technology	Wuhan	Hubei

Sponsors (1)

Lead Sponsor	Collaborator
Wuhan Union Hospital, China

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Fasting insulin and blood VEGF-B levels	To investigate the relationship between blood pressure, BMI, fasting blood glucose, fasting blood lipids and fasting insulin and blood VEGF-B levels.	3 days
Secondary	The methylation status of VEGF-B gene promoter region and VEGF-B genomic protein methylation level .	To investigate the relationship between the methylation status of VEGF-B gene promoter region and VEGF-B genomic protein methylation level and obesity and metabolic disorders.	7 days